Cancer treatment with epothilones
AssigneeNovartis AG
InventorsTerence O'Reilly, Markus Wartmann, Manuel Litchman, Pamela Cohen
Life of this patent
Estimating the term…
Abstract
The invention relates to the treatment of a proliferative disease, especially according to certain treatment regimens, with an epothilone, especially with epothilone A and more preferably epothilone B; as well as to the treatment of certain cancers with such an epothilone.
Claims18
A method of treating a gastrointestinal tumor which comprises the step of administering to a human in need of such treatment more than one dose of epothilone B wherein there is an interval of from one to six weeks between administration of each dose and wherein the amount of epothilone B adminstered in each dose is calculated according to the formula where N is the number of weeks between administration of the dose of epothiline B and y is 6.
A method of treating a prostate tumor that is refractory to hormone treatment which comprises the step of administering to a human in need of such treatment more than one dose of epothilone B wherein there is an interval of from one to six weeks between administration of each dose and wherein the amount of epothilone B adminstered in each dose is calculated according to the formula
- single dose(mg/m2)=(0.1 to y)×N
- where N is the number of weeks between administration of the dose of epothiline B and y is 6.
A method of claim 6 wherein y is 2.5.
- 8.A method of claim 7 wherein the interval is 1, 2 or 3 weeks.
A method of treating a proliferative disease, which comprises the step of administering to a human in need of such treatment more than one dose of epothilone B wherein there is an interval of from one to six weeks between administration of each dose and wherein the amount of epothilone B adminstered in each dose is calculated according to the formula
- single dose(mg/m2)=(0.1 to y)×N
- where N is the number of weeks between administration of the dose of epothiline B and y is 6 and the proliferative disease is refractory to one or more chemotherapeutic agents and is selected from the group consisting of melanoma, ovarian cancer, pancreas cancer, neuroblastoma, head and neck cancer bladder cancer, renal cancer, brain cancer, and gastric cancer.
A method of treating a proliferative disease, which comprises the step of administering to a human in need of such treatment more than one dose of epothilone B wherein there is an interval of from one to six weeks between administration of each dose and wherein the amount of epothilone B adminstered in each dose is calculated according to the formula
- single dose(mg/m2)=(0.1 to y)×N
- where N is the number of weeks between administration of the dose of epothiline B and y is 6 and the proliferative disease is adenocarcimoma.
Dependencies are inferred from the claim text.